| |
Gilead CEO Comments/Remdesivir Compassionate Access Results
|
| |
| |
3 pdfs attached
Download the PDF here
Download the PDF here
Download the PDF here
Begin forwarded message:
From: Advocacy at Gilead Sciences
To: Advocacy at Gilead Sciences
Subject: An Update from Gilead Sciences
Date: April 10, 2020 at 10:18:16 PM EDT
To our community partners,
As we have been doing since the beginning of the COVID-19 outbreak, we would like to share with you the latest information on our work to respond to the urgent medical needs presented by the pandemic.
Please see the attached press release and update from our Chairman and CEO, Daniel O’Day, regarding the publication of early data in The New England Journal of Medicine.
Thank you,
Gilead Sciences Advocacy Team
We expect that we will have preliminary data from the study of remdesivir in severe patients at the end of April and will work quickly to interpret and share the findings.
|
|
| |
| |
|
|
|
